Earnings digests and industry comparisons for Japan's biggest listed companies.
24 reports(page 2 of 2)
Peptide Dream's first-half FY2026 revenue grew 8.0% to ¥9.226 billion, and its operating loss narrowed to ¥2.534 billion from ¥2.625 billion. Radiopharmaceuticals drove growth, cushioning drug discovery losses. It expects a full-year operating profit of ¥4.6 billion on ¥32 billion revenue.
Q2 FY2026 (Jan-Jun 2026)
Kobayashi's H1 FY2026 revenue rose 2.5% to ¥70,749 million, but operating profit fell 67.5% to ¥2,162 million amid beni-koji fallout and ad spending. Full-year net profit is seen surging 173.5% to ¥10,000 million on a share sale gain.
FY2026 H1 (January–June 2026)
Nippon Shinyaku posted a 24.1% year-on-year increase in revenue to 49,066 million yen for the first quarter of FY2027, driven by strong sales of new drugs Aririda and Fintepla. Operating profit rose 22.1% to 12,311 million yen, while net income attributable to owners of the parent climbed 22.5% to 10,109 million yen, a record first-quarter profit.
FY2027 Q1 (Apr-Jun 2026)
Eisai's revenue for the first quarter of FY2027 (April-June 2026) rose 15.6% to ¥234.3 billion, driven by robust global sales of its three key products: Lenvima, Leqembi, and Dayvigo. Net profit attributable to owners of the parent climbed 26.0% to ¥18.2 billion, while a weak yen also provided a tailwind.
FY2027 Q1 (Apr-Jun 2026)
Astellas posted Q1 FY2027 revenue of ¥640.9bn (+26.7% YoY), operating profit of ¥184.5bn (+94.9%) and net profit of ¥141.8bn (+107.3%). Strategic products PADCEV and IZERVAY, along with XTANDI, drove growth, supported by a weak yen. Full-year guidance was maintained, with Q1 progress at 28.9% for revenue and 46.7% for operating profit.
Q1 FY2027 (Apr-Jun 2026)
Kyowa Kirin's global revenue rose 15% to ¥145.2 billion in Q2 FY2026, while core operating profit surged 80% to ¥46.1 billion, driven by strong Crysvita sales and a weak yen. The core margin hit 31.8%.
FY2026 Q2 (Apr-Jun 2026)
Otsuka Holdings reported double-digit revenue and profit growth for the first half of fiscal 2026, driven by strong sales of Rexulti and new drug Voyzact, leading to a sharp upward revision of its full-year guidance.
FY2026 Q2 (Jan-Jun 2026)
Sumitomo Pharma reported a 19.9% jump in revenue to ¥129.5 billion for the first quarter of its fiscal year ending March 2027, but core operating profit fell 11.0% to ¥18.1 billion. The bottom line got a boost from a sharp swing to foreign exchange gains, lifting net profit 51.7% to ¥17.0 billion.
FY2027 Q1 (Apr-Jun 2026)
Takeda reported a 10.2% rise in revenue to ¥1,219.9 billion for the first quarter of FY2027, but the gain was entirely driven by a weaker yen; on a constant currency basis, revenue edged down 0.5%. Operating profit climbed 9.1% to ¥201.4 billion, while net income attributable to owners fell 8.9% to ¥113.2 billion, reflecting higher tax expenses.
Q1 FY2027 (Apr-Jun 2026)
Takeda reported that the US Food and Drug Administration has accepted its new drug application for the psoriasis treatment zasocitinib. The approval target date is set for the first quarter of 2027 following the priority review status.
Daiichi Sankyo has secured a complete victory in its long-running legal dispute with NTK, as the Tokyo District Court dismissed all of the opponent's claims on September 10, 2026.
Otsuka Holdings (4578) on the 28th raised its first-half FY2026 net profit forecast by 68% to ¥215 billion, marking a record high. The upgrade was fueled by brisk sales of mainstay drugs, a weaker yen, and restrained R&D expenses.
